Blog

Are you risking your entire drug patent strategy with one simple oversight? Dosage regimen patents have become a minefield for pharmaceutical companies, with even the smallest misstep leading to costly rejections. Whether you're struggling to navigate the EPO's inventive step requirements or facing setbacks from clinical trial disclosures, securing a strong dosage patent has never been more challenging. But why are so many companies still getting it wrong? And what crucial strategies are being overlooked in jurisdictions like the UK and US? Keep reading as we reveal the hidden pitfalls and insider tips that could make or break your next dosage regimen patent.

The upcoming AIPPI Japan seminar titled "International Patent Drafting and Protection: Insights from the U.S., India, and Germany" will take place on September 12, 2024...

In preliminary injunction proceedings before the Munich Local Division, our firm, together with attorneys from law firm, Fieldfisher, was able to obtain a preliminary injunction for our client Syngenta against Sumi Agro. The subject matter of the patent, EP 2 152 073, is a herbicide composition. The local division found ...

However, decision does not open a new chapter in Europe’s view on epitope based claims